Drug Trial Radar · NCT04659304
Study Evaluating Safety and Tolerability of Allocetra-OTS in Patients With COVID-19
Last checked: Nov 19, 2026Latest source record: Aug 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
18
Planned (sponsor's estimate)
Start
Dec 2021
Primary completion
Sep 2022
Study completion Dec 2022
Sponsor
- Lead sponsor
- Enlivex Therapeutics Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1b, multi-center, open label, sequential dose escalation trial assessing 3 dose cohorts using a 3+3 design to evaluate safety and tolerability of Allocetra-OTS in adult patients with moderate COVID-19. The sample size for this trial is anticipated to range from 9 to 18 patients.
Conditions
- Covid19
Interventions
Allocetra-OTSDrug
Cell-based therapy comprised of allogeneic non-HLA matched peripheral blood mononuclear cells induced to an early apoptotic state.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - Adverse EventsTime frame: 28 days
- Maximum Tolerated Dose (MTD)Time frame: 28 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.